ERBB2 and glioblastoma: In the present study, canine osteosarcoma, human osteosarcoma and glioblastoma cell lines, exhibited similar response to single CT treatment and cancer cell death was further enhanced by introducing another STAT3/5 inhibitor, a proteasome inhibitor drug, and an EGFR/ErbB2 inhibitor.